TherapeuticsMD (NASDAQ:TXMD) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research report sent to investors on Tuesday. The brokerage issued a hold rating on the stock.

TherapeuticsMD Stock Performance

Shares of TXMD stock opened at $1.96 on Tuesday. TherapeuticsMD has a 12-month low of $1.84 and a 12-month high of $4.73. The firm has a 50 day moving average price of $2.17 and a two-hundred day moving average price of $2.27.

Institutional Trading of TherapeuticsMD

An institutional investor recently bought a new position in TherapeuticsMD stock. ADAR1 Capital Management LLC bought a new stake in TherapeuticsMD, Inc. (NASDAQ:TXMD) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 272,160 shares of the company’s stock, valued at approximately $612,000. ADAR1 Capital Management LLC owned 2.57% of TherapeuticsMD as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 30.74% of the company’s stock.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.